Insulin resistance can result in the development of type 2 diabetes
The FDA permits compounding only when a drug is officially in shortage, and both semaglutide and tirzepatide were removed from the shortage list in late 2024 and early 2025
Neither high (Figure 5, group 2) nor low levels (Figure 5, groups 5 and 7) of plasma medium and long chain acylcarnitines noted in our work correlate with described genetic disorders of mitochondrial fatty acid or organic acid metabolism in humans (64)
It can also reduce the strain of unmanaged chronic conditions
Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S (January 2008)
Once frozen, the damage is done